Recro Pharma, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, signed a master supply and services agreement with Otsuka Pharmaceutical Co., Ltd. Under terms of the agreement, Recro will serve as a commercial manufacturing and supplier for Otsuka.
 
“The opportunity to support Otsuka’s supply chain risk management efforts while serving as their U.S.-based supply source represents a key milestone for Recro and underscores the continued momentum our company is generating in growing our CDMO business and diversifying our client base,” said David Enloe, CEO, Recro. “This is a significant win for Recro and is a testimony to the hard work our tech transfer and production teams have put in over the past several quarters to get us to this point. We look forward to a long and productive collaboration with the Otsuka team as we support them in achieving commercial success across their product portfolio.
 
“Beyond our work with Otsuka, we believe this agreement highlights Recro’s ability to serve as a trusted U.S. supply source for other developers of small molecule therapeutics, thus helping to mitigate the growing global supply chain risk facing the biopharmaceutical industry.”